Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Asfotase alfa, sold under the brand name Strensiq, is a medication used in the treatment of people with perinatal/infantile- and juvenile-onset hypophosphatasia.[3][4][5][6]
Asfotase alfa is an enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP). Hypophosphatasia is caused by a genetic defect of tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme that plays a role in bone mineralization. Asfotase alfa is a recombinant glycoprotein that contains the catalytic domain (the active site) of TNSALP. It is therefore used as an enzyme replacement therapy
| Products Name (INN Index) | Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant) |
|---|---|
| INN Name | asfotase alfa |
| Target | Enzyme |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase) 18- 502]2 – IGHG1 Fc (Fragment constant) – Asp-Ile- deca-aspartate |
| VD LC | Fusion – [ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase) 18- 502]2 – IGHG1 Fc (Fragment constant) – Asp-Ile- deca-aspartate |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Alexion Pharmaceuticals Inc. (New Haven CT USA) / Enobia pharma (Cambridge MA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Enzyme |
| Package |
